The US Anti-Doping Agency (USADA) has partnered with Epicore to develop a sweat-sensing technology as a method of drug detection.
Epicore’s wearable sweat-collection device, Discovery Patch, is expected to provide a non-invasive alternative to current standards such as blood and urine samples for anti-doping. The wearable can also provide real-time health data that athletes can use to optimise their performance.
The Discovery Patch comprises of wearable microfluidic patch that captures eccrine sweat directly from the skin during exercise, environmental exposure, and pharmacologic modes of sweat induction. Sweat is transferred from the microfluidic patch to clean lab storage containers using a sweat extraction apparatus designed to rapidly collect and prepare sweat samples for biochemical analysis.
The USADA and Epicore’s current partnership is based on a 2023 proof-of-concept study conducted by the two organisations. The study showed that Epicore’s patch can collect sweat samples easily and reliably from multiple locations on the body. These samples can be used for drug and hydration analysis.
According to a GlobalData report, the market size of wearable technology in the medical sector in 2023 exceed $100bn. The market is expected to grow at a compound annual growth rate (CAGR) of 15% up to 2030.
Last month, Epicore received investments from Pegasus Tech Ventures and Japanese Denka Company to scale and distribute its wearables in Japan and Asian markets. The connected hydration wearable tracker device is designed to monitor sweat volume loss, electrolyte loss, body temperature, and body movement. It can provide heat injury alerts and predict dehydration events.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOther companies developing wearables include Empatica. In December 2023, the company stated its intention to develop a clinical trial for an artificial intelligence (AI)-assisted wearable device to predict refractory seizures. The trial is expected to start enrolment this year.
In October 2023, California-based start-up CARI Health has a $2.8m fast-track grant to bring its wearable medication monitor to market in the US. The device is expected to be used to curb overdose rates and drug abuse.